Management of serious meticillin-resistant Staphylococcus aureus infections: What are the limits?

International Journal of Antimicrobial Agents

Volumn 37, Issue 3, 2011, Pages 202-209

  Gould, Ian M ^a   Cauda, Roberto ^b   Esposito, Silvano ^c   Gudiol, Francesco ^d   Mazzei, Teresita ^e   Garau, Javier ^f  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b CATHOLIC UNIVERSITY   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSITY OF FLORENCE   (Italy)

^f HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

Antibiotics; MIC drift; MRSA treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; CHLORAMPHENICOL; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; GENTAMICIN; GLYCOPEPTIDE; ICLAPRIM; LINEZOLID; METICILLIN; ORITAVANCIN; PENICILLIN G; RETAPAMULIN; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; BONE MARROW TOXICITY; CATHETER INFECTION; COMMUNICABLE DISEASE; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITAL INFECTION; HUMAN; INFECTIOUS PNEUMONIA; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SEPSIS; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; WOUND INFECTION;

EID: 79951860177     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.10.030     Document Type: Short Survey

References (86)

1. European Antimicrobial Resistance Surveillance System Annual Report, 2008. Bilthoven, The Netherlands: National Institute for Public Health and the Environment; 2009.
2. S.E. Cosgrove, G. Sakoulas, E.N. Perencevich, M.J. Schwaber, A.W. Karchmer, and Y. Carmeli Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis Clin Infect Dis 36 2003 53 59 (Pubitemid 36099097)
3. M. Melzer, S.J. Eykyn, W.R. Gransden, and S. Chinn Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia Clin Infect Dis 37 2003 1453 1460 (Pubitemid 37494672)
4. S. Shurland, M. Zhan, D.D. Bradham, and M.C. Roghmann Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus Infect Control Hosp Epidemiol 28 2007 273 279 (Pubitemid 46480725)
5. Z. Athanassa, I.I. Siempos, and M.E. Falagas Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review Eur Respir J 28 2008 625 632
6. J. Garau, E. Bouza, J. Chastre, F. Gudiol, and S. Harbarth Management of methicillin-resistant Staphylococcus aureus infections Clin Microbiol Infect 15 2009 125 136
7. A. Hussain, S. Alleyne, and D. Jenkins A survey of attitudes towards methicillin-resistant Staphylococcus aureus bacteraemias amongst United Kingdom microbiologists J Antimicrob Chemother 65 2010 347 349
8. S. Deresinski Counterpoint: Vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence Clin Infect Dis 44 2007 1543 1548 (Pubitemid 46871499)
9. J.F. Mohr, and B.E. Murray Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus Clin Infect Dis 44 2007 1536 1542 (Pubitemid 46871498)
10. R.G. Wunderink, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, and M.H. Kollef Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia Chest 124 2003 1789 1797 (Pubitemid 37433574)
11. M.H. Kollef, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, and R.G. Wunderink Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin Intensive Care Med 30 2004 388 394 (Pubitemid 38375611)
12. G. Wang, J.F. Hindler, K.W. Ward, and D.A. Bruckner Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period J Clin Microbiol 44 2006 3883 3886 (Pubitemid 44737223)
13. G. Steinkraus, R. White, and L. Friedrich Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 J Antimicrob Chemother 60 2007 788 794 (Pubitemid 47434257)
14. R.L. Holmes, and J.A. Jorgensen Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006 Antimicrob Agents Chemother 52 2008 757 760 (Pubitemid 351170860)
15. R. Hope, D.M. Livermore, G. Brick, M. Lillie, R. Reynolds BSAC Working Parties on Resistance Surveillance Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06 J Antimicrob Chemother 62 Suppl. 2 2008 ii65 ii74
16. V. Prakash, J.S. Lewis 2nd, and J.H. Jorgensen Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used Antimicrob Agents Chemother 52 2008 4528
17. H.S. Sader, P.R. Rhomberg, and R.N. Jones Nine-hospital study comparing broth microdilution and E-test method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 53 2009 3162 3165
18. K.C. Horne, B.P. Howden, E.A. Grabsch, M. Graham, P.B. Ward, and S. Xie Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA Antimicrob Agents Chemother 53 2009 3447 3452
19. I.G. Bae, J.J. Federspiel, J.M. Miró, C.W. Woods, L. Park, and M.J. Rybak Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance J Infect Dis 200 2009 1355 1366
20. Y. Maor, M. Hagin, N. Belausov, N. Keller, D. Ben-David, and G. Rahav Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia J Infect Dis 199 2009 619 624
21. P.G. Charles, P.B. Ward, P.D. Johnson, B.P. Howden, and M.L. Grayson Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus Clin Infect Dis 38 2004 448 451 (Pubitemid 38200128)
22. B.P. Howden, P.B. Ward, P.G. Charles, T.M. Korman, A. Fuller, and P. du Cros Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility Clin Infect Dis 38 2004 521 528 (Pubitemid 38250962)
23. J.I. Alós, A. García-Cañas, P. García-Hierro, and F. Rodríguez-Salvanés Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage J Antimicrob Chemother 62 2008 773 775
24. O. Gasch, J. Ayats, M. Dominguez, F. Tubau, J. Liñares, and C. Peña Secular trends in the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in a university hospital 49th Interscience Conference on Antimicrobial Agents And Chemotherapy (ICAAC), 12-15 September 2009 San Francisco, CA 2009 ASM Press Washington, DC [Abstract K-1630]
25. R.N. Jones Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains Clin Infect Dis 42 Suppl. 1 2006 S13 S24
26. P.A. Moise, D.S. Smyth, N. El-Fawal, D.A. Robinson, P.N. Holden, and A. Forrest Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia J Antimicrob Chemother 61 2008 85 90
27. P. Moise-Broder, N. El-Fawal, A. Forrest, J. Schentag, and G. Sakoulas Relationship of prior vancomycin use and daptomycin MICs in patients with MRSA bacteremia 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 27-30 September 2006 San Francisco, CA 2006 ASM Press Washington, DC [Abstract C2-1151]
28. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
29. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 1.0. Basel, Switzerland: EUCAST; 2009.
30. P.A. Moise-Broder, A. Forrest, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections Clin Pharmacokinet 43 2004 925 942 (Pubitemid 39447034)
31. G. Sakoulas, P.A. Moise-Broder, J. Schentag, A. Forrest, R.C. Moellering Jr., and G.M. Eliopoulos Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 42 2004 2398 2402 (Pubitemid 38747480)
32. L.K. Hidayat, D.I. Hsu, R. Quist, K.A. Shriner, and A. Wong-Beringer High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity Arch Intern Med 166 2006 2138 2144 (Pubitemid 44631403)
33. P.A. Moise, G. Sakoulas, A. Forrest, and J.J. Schentag Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia Antimicrob Agents Chemother 51 2007 2582 2586 (Pubitemid 47047340)
34. T.P. Lodise, J. Graves, A. Evans, E. Graffunder, M. Helmecke, and B.M. Lomaestro Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin Antimicrob Agents Chemother 52 2008 3315 3320
35. A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, and V.P. Dimova Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 46 2008 193 200 (Pubitemid 351269157)
36. D.I. Hsu, L.K. Hidayat, R. Quist, J. Hindler, A. Karlsson, and A. Yusof Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections Int J Antimicrob Agents 32 2008 378 385
37. M.J. Rybak, B.M. Lomaestro, J.C. Rotscahfer, R.C. Moellering, W.A. Craig, and M. Billeter Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists Clin Infect Dis 49 2009 325 327
38. M.N. Jeffres, W. Isakow, J.A. Doherty, P.S. McKinnon, D.J. Ritchie, and S.T. Micek Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices Chest 130 2006 947 955 (Pubitemid 44583720)
39. T.P. Lodise, N. Patel, B.M. Lomaestro, K.A. Rodvold, and G.L. Drusano Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients Clin Infect Dis 49 2009 507 514
40. T.P. Lodise, B. Lomaestro, J. Graves, and G.L. Drusano Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity Antimicrob Agents Chemother 52 2008 1330 1336 (Pubitemid 351521995)
41. N. Markowitz, E.L. Quinn, and L.D. Saravolatz Trimethoprim- sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection Ann Intern Med 117 1992 390 398
42. V.G. Fowler, H.W. Boucher, G.R. Corey, E. Abrutyn, A.W. Karchmer, and M.E. Rupp Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus N Engl J Med 355 2006 653 665
43. M.H. Kollef, L.M. Napolitano, J.S. Solomkin, R.G. Wunderink, I.G. Bae, and V.G. Fowler Health care-associated infection (HAI): a critical appraisal of the emerging threat - proceedings of the HAI Summit Clin Infect Dis 47 Suppl. 2 2008 S55 S99
44. S. Svetitsky, L. Leibovici, and M. Paul Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis Antimicrob Agents Chemother 53 2009 4069 4079
45. A. Kirby, R. Graham, N.J. Williams, M. Wootton, C.M. Broughton, and M. Alanazi Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK J Antimicrob Chemother 65 2010 721 724
46. A.P. Wilson Clinical pharmacokinetics of teicoplanin Clin Pharmacokinet 39 2000 167 183
47. R.S. Dykhuizen, G. Harvey, N. Stephenson, D. Nathwani, and I.M. Gould Protein binding and serum bactericidal activities of vancomycin and teicoplanin Antimicrob Agents Chemother 39 1995 1842 1847
48. D.J. Stalker, and G.L. Jungbluth Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial Clin Pharmacokinet 42 2003 1129 1140 (Pubitemid 37357649)
49. L. Beibei, C. Yun, C. Mengli, B. Nan, Y. Xuhong, and W. Rui Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials Int J Antimicrob Agents 35 2010 3 12
50. M.E. Falagas, I.I. Siempos, and K.Z. Vardakas Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials Lancet Infect Dis 8 2008 53 66 (Pubitemid 351620940)
51. F.W. Goldstein, V. Zeller, N. Desplaces, and M.D. Kitzis Linezolid (Lin) serum levels: one size doesn't fit all! 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 27-30 September 2006 San Francisco, CA 2006 ASM Press Washington, DC [Abstract A1945]
52. C. Adembri, S. Fallani, M.I. Cassetta, S. Arrigucci, A. Ottaviano, and P. Pecile Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion Int J Antimicrob Agents 31 2008 122 129
53. S. Kohno, K. Yamaguchi, N. Aikawa, Y. Sumiyama, S. Odagiri, and N. Aoki Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan J Antimicrob Chemother 60 2007 1361 1369 (Pubitemid 350168334)
54. US Food and Drug Administration. Information for healthcare professionals: linezolid (marketed as Zyvox). Silver Spring, MD: FDA; 16 March 2007.
55. R.N. Jones, J.E. Ross, M. Castanheira, and R.E. Mendes United States resistance surveillance results for linezolid (LEADER Program for 2007) Diagn Microbiol Infect Dis 62 2008 416 426
56. K.S. Long, J. Poehlsgaard, C. Kehrenberg, S. Schwarz, and B. Vester The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics Antimicrob Agents Chemother 50 2006 2500 2505 (Pubitemid 43993192)
57. C.A. Arias, M. Vallejo, J. Reyes, D. Panesso, J. Moreno, and E. Castañeda Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase J Clin Microbiol 46 2008 892 896 (Pubitemid 351379975)
58. R.E. Mendes, L.M. Deshpande, M. Castanheira, J. DiPersio, M.A. Saubolle, and R.N. Jones First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States Antimicrob Agents Chemother 52 2008 2244 2246 (Pubitemid 351758569)
59. M. Sánchez García, M.A. De la Torre, G. Morales, B. Peláez, M.J. Tolón, and S. Domingo Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit JAMA 303 2010 2260 2264
60. K. Yoshida, H. Shoji, H. Hanaki, C. Yanagisawa, Y. Ikeda-Dantsuji, and K. Fukuchi Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid J Infect Chemother 15 2009 417 419
61. S.J. Rehm, H. Boucher, D. Levine, M. Campion, B.I. Eisenstein, and G.A. Vigliani Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates J Antimicrob Chemother 62 2008 1413 1421
62. N. Patel, P. Lubanski, S. Ferro, M. Bonafede, S. Harrington, and A. Evans Correlation between vancomycin MIC values and those of other agents against Gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 53 2009 5141 5144
63. M.K. Hayden, K. Rezai, R.A. Hayes, K. Lolans, J.P. Quinn, and R.A. Weinstein Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus J Clin Microbiol 43 2005 5285 5287 (Pubitemid 41484040)
64. T. Jones, M.R. Yeaman, G. Sakoulas, S.J. Yang, R.A. Proctor, and H.G. Sahl Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding Antimicrob Agents Chemother 52 2008 269 278
65. N.N. Mishra, S.J. Yang, A. Sawa, A. Rubio, C.C. Nast, and M.R. Yeaman Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 53 2009 2312 2318
66. M. Benvenuto, D.P. Benziger, S. Yankelev, and G. Vigliani Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers Antimicrob Agents Chemother 50 2006 3245 3249 (Pubitemid 44527494)
67. P.A. Moise, E. Hershberger, M.I. Amodio-Groton, and K.C. Lamp Safety and clinical outcomes when utilizing high-dose (≥8 mg/kg) daptomycin therapy Ann Pharmacother 43 2009 1211 1219
68. O. Burkhardt, and J.T. Kielstein A simplified three-times weekly daptomycin dosing regimen for chronic hemodialysis patients Expert Rev Anti Infect Ther 8 2010 11 14
69. N.N. Salama, J.H. Segal, M.D. Churchwell, J.H. Patel, L. Gao, and M. Heung Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients Nephrol Dial Transplant 25 2010 1279 1284
70. S.D. Putnam, H.S. Sader, D.J. Farrell, and R.N. Jones Sustained antimicrobial activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States medical centers from 2004 through 2008 J Chemother 22 2010 13 16
71. J.M. Míro, A. del Río, A. Moreno, C. Pea, C. Cervera, and D. Soy Efficacy and safety of fosfomycin (F) plus imipenem (I) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) native valve endocarditis (NVE): preliminary results of a clinical trial 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008 Washington, DC 2008 ASM Press Washington, DC
72. M.E. Stryjewski, D.R. Graham, S.E. Wilson, W. O'Riordan, D. Young, and A. Lentnek Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms Clin Infect Dis 46 2008 1683 1693 (Pubitemid 351706765)
73. Pfizer Inc. Pfizer will withdraw global marketing applications for dalbavancin to conduct a new trial. Pfizer press release. 9 September 2008 http://www.businesswire.com/portal/site/pfizer/permalink/?ndmViewId= news-view&newsId=20080909005943&newsLang=en [accessed 30 November 2010].
74. European Medicines Agency. Questions and answers on the withdrawal of the marketing authorisation application for Ramvocid (oritavancin). EMEA/554626/2009. London, UK: EMEA; 24 September 2009.
75. Johnson & Johnson. FDA issues complete response letter for ceftobiprole. Press release. 30 December 2009. Raritan, NJ: Johnson & Johnson; 2009 http://www.jnj.com/connect/news/all/20091230-090000 [accessed 10 May 2010].
76. European Medicines Agency. Questions and answers: refusal of the marketing approval for Zeftera (ceftobiprole). EMA/83783/2010. London, UK: EMEA; 18 February 2010.
77. G.J. Noel, R.S. Strauss, A. Shah, P. Bagchi BAP00248/307 Study Group Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008 Washington, DC 2008 ASM Press Washington, DC [Abstract K-486]
78. L. Saravolatz, J. Pawlak, and L. Johnson In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates Antimicrob Agents Chemother 54 2010 3027 3030
79. C. Jacqueline, G. Amador, J. Caillon, V. Le Mabecque, E. Batard, and A.F. Migeville Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis J Antimicrob Agents 65 2010 1749 1752
80. C. Jacqueline, J. Caillon, E. Batard, V. Le Mabecque, G. Amador, and Y. Ge Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model J Antimicrob Agents 65 2010 2264 2265
81. G.R. Corey, M. Wilcox, G.H. Talbot, H.D. Friedland, T. Baculik, and G.W. Witherell Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection Clin Infect Dis 51 2010 641 650
82. Arpida. Arpida withdraws European marketing application for intravenous iclaprim in cSSTI as a result of negative outcome of CHMP hearing. Press release 20 October 2009. Reinach, Switzerland: Evolva/Arpida; 2009. http://www.evolva.com/newsroom/2009/10/20/53/arpida-withdraws-european- marketing-application-intravenous-iclaprim-cssti-re [accessed 1 May 2010].
83. S. Harbarth, P.M. Hawkey, F. Tenover, S. Stefani, A. Pantosti, and M.J. Struelens Update on screening and clinical diagnosis of meticillin-resistant Staphylococcus aureus Int J Antimicrob Agents 2010 10.1016/j.ijantimicag.2010. 10.022
84. B. Cookson, M.J.M. Bonten, F.M. MacKenzie, R.L. Skov, H.A. Verbrugh, and E. Tacconelli Meticillin-resistant Staphylococcus aureus (MRSA): Screening and de-colonisation Int J Antimicrob Agents 37 2011 195 201
85. S.E. Cosgrove, G.A. Vigliani, V.G. Fowler, E. Abrutyn, G.R. Corey, and D.P. Levine Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic Clin Infect Dis 48 2009 713 721
86. M. Kunkel, J.E. Chastre, M. Kollef, M. Niederman, A.F. Shorr, and R.G. Wunderink Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), 21-24 October 2010 Vancouver, British Columbia, Canada 2010 [Abstract 5047]